Stock Track | DaVita Plummets 5.05% as Multiple Analysts Cut Price Targets

Stock Track10-31

DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider faced downward pressure following a series of analyst reports that expressed concerns about the company's near-term prospects.

Barclays led the bearish sentiment by reducing its price target for DaVita from $149 to $143, while maintaining an Equal-Weight rating on the stock. Deutsche Bank took an even more cautious stance, cutting its target price more significantly from $137 to $126. These downward revisions suggest that analysts are adjusting their expectations for DaVita's future performance.

Despite the stock's sharp decline, the overall analyst consensus remains cautious. According to data from FactSet, DaVita currently has an average rating of "hold" with a mean price target of $147. This indicates that while analysts see potential upside from current levels, they also recognize challenges that could impact the company's growth. Investors will likely be closely watching DaVita's upcoming financial results and management commentary for further insights into the factors driving these analyst revisions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107003362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 03:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107003362","market":"sg","top_or_hot":-1,"title":"Stock Track | DaVita Plummets 5.05% as Multiple Analysts Cut Price Targets","media":"Stock Track","content":"<p>DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider faced downward pressure following a series of analyst reports that expressed concerns about the company's near-term prospects.</p>\n\n<p>Barclays led the bearish sentiment by reducing its price target for DaVita from $149 to $143, while maintaining an Equal-Weight rating on the stock. Deutsche Bank took an even more cautious stance, cutting its target price more significantly from $137 to $126. These downward revisions suggest that analysts are adjusting their expectations for DaVita's future performance.</p>\n\n<p>Despite the stock's sharp decline, the overall analyst consensus remains cautious. According to data from FactSet, DaVita currently has an average rating of \"hold\" with a mean price target of $147. This indicates that while analysts see potential upside from current levels, they also recognize challenges that could impact the company's growth. Investors will likely be closely watching DaVita's upcoming financial results and management commentary for further insights into the factors driving these analyst revisions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DaVita Plummets 5.05% as Multiple Analysts Cut Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DaVita Plummets 5.05% as Multiple Analysts Cut Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 03:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider faced downward pressure following a series of analyst reports that expressed concerns about the company's near-term prospects.</p>\n\n<p>Barclays led the bearish sentiment by reducing its price target for DaVita from $149 to $143, while maintaining an Equal-Weight rating on the stock. Deutsche Bank took an even more cautious stance, cutting its target price more significantly from $137 to $126. These downward revisions suggest that analysts are adjusting their expectations for DaVita's future performance.</p>\n\n<p>Despite the stock's sharp decline, the overall analyst consensus remains cautious. According to data from FactSet, DaVita currently has an average rating of \"hold\" with a mean price target of $147. This indicates that while analysts see potential upside from current levels, they also recognize challenges that could impact the company's growth. Investors will likely be closely watching DaVita's upcoming financial results and management commentary for further insights into the factors driving these analyst revisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVA","symbol_name":"达维塔保健","start_time":0,"source_url":"","article_id":"1107003362","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107003362","pubTimestamp":1761851649,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVA":"达维塔保健"},"translate_title":"个股追踪|DaVita暴跌5.05%多分析师下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":1},"content_text":"DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider faced downward pressure following a series of analyst reports that expressed concerns about the company's near-term prospects.\nBarclays led the bearish sentiment by reducing its price target for DaVita from $149 to $143, while maintaining an Equal-Weight rating on the stock. Deutsche Bank took an even more cautious stance, cutting its target price more significantly from $137 to $126. These downward revisions suggest that analysts are adjusting their expectations for DaVita's future performance.\nDespite the stock's sharp decline, the overall analyst consensus remains cautious. According to data from FactSet, DaVita currently has an average rating of \"hold\" with a mean price target of $147. This indicates that while analysts see potential upside from current levels, they also recognize challenges that could impact the company's growth. Investors will likely be closely watching DaVita's upcoming financial results and management commentary for further insights into the factors driving these analyst revisions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107003362","isCrawlerRequest":true}